PerkinElmer Aktie
114,92USD | 3,12USD | 2,79% |
WKN: 850943 / ISIN: US7140461093
Personal
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 14 000 | 16 700 | 16 700 | 11 500 | 0 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,27 | 0,30 | 0,20 | 0,24 | 0,00 |
Bilanz (in Mio. USD) - Aktiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 2 239 | 2 441 | 3 289 | 3 001 | 2 350 |
Summe Anlagevermögen | 5 721 | 12 560 | 10 841 | 10 564 | 10 043 |
Summe Aktiva | 7 960 | 15 001 | 14 130 | 13 565 | 12 392 |
Bilanz (in Mio. USD) - Passiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Fremdkapital | 4 225 | 7 859 | 6 747 | 5 692 | 4 726 |
Summe Eigenkapital | 3 735 | 7 141 | 7 383 | 7 873 | 7 667 |
Summe Passiva | 7 960 | 15 001 | 14 130 | 13 565 | 12 392 |
Adresse
77 Citypoint 4th Avenue, 02451 Waltham | |
Telefon | +1 (877) 373-6374 |
Internet | http://www.revvity.com |
Management
Alexis Platon Michas
Non-Executive Chairman |
Anita Gonzales
Vice President & Controller |
Arvind Sundar Rajan
Vice President-Digital & Technology |
Bryan A. Kipp
VP & General Manager-Life Sciences Integration |
Daniel R. Tereau
Senior VP-Strategy & Business Development |
Franklin R. Witney
Independent Director |
Jayashree Kailas Thacker
Chief Information Officer & Senior Vice President |
Joel S. Goldberg
Secretary, SVP-Administration & General Counsel |
Madhuri Hegde
Chief Scientific Officer & Senior Vice President |
Magali Four
Chief People & Culture Officer & SVP |
Maxwell Krakowiak
Chief Financial Officer & Senior Vice President |
Michael Klobuchar
Independent Director |
Michel Pericles Vounatsos
Independent Director |
Michelle McMurry-Heath
Independent Director |
Miriame Victor
Chief Commercial Officer & Senior Vice President |
Pascale Witz
Independent Director |
Peter Barrett
Independent Director |
Prahlad Ramadhar Singh
President, Chief Executive Officer & Director |
Samuel Ross Chapin
Independent Director |
Sophie V. Vandebroek
Independent Director |
Steve Willoughby
Vice President-Investor Relations |
Tajinder S. Vohra
Senior Vice President-Global Operations |
Yi Ping Lin
Chief Quality, Regulatory & Clinical Officer |